Related Experiment Videos
Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome
Wilhelmina G Leen1, Corry M Weemaes, Marcel M Verbeek
1Department of Pediatric Neurology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. W.Leen@neuro.umcn.nl
We describe 2 children with postinfectious opsoclonus-myoclonus syndrome. Although the patients initially responded to monotherapy with methylprednisolone, intravenous immunoglobulins, or rituximab, they manifested persistent neurologic deficits and relapsing signs. Treatment with rituximab in combination with intravenous immunoglobulin, however, resulted in significant longterm clinical improvement.
We describe 2 children with postinfectious opsoclonus-myoclonus syndrome. Although the patients initially responded to monotherapy with methylprednisolone, intravenous immunoglobulins, or rituximab, they manifested persistent neurologic deficits and relapsing signs. Treatment with rituximab in combination with intravenous immunoglobulin, however, resulted in significant longterm clinical improvement.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myocarditis III: Medical Management
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Nephrotic Syndrome II : Assessment and Medical Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Respiratory Syncytial Virus Disease